Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management

Area of Science:

• Oncology
• Immunotherapy
• Neurology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
• ICIs target programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathways.
• These pathways normally regulate immune responses to prevent autoimmunity.

Purpose of the Study:

• To review the neurologic adverse events associated with immune checkpoint inhibitors.
• To highlight the importance of recognizing and managing these rare but significant toxicities.

Main Methods:

• Literature review of studies reporting neurologic adverse events from ICIs.
• Analysis of described neurological manifestations and their clinical implications.

Main Results:

• Neurologic adverse events include encephalitis, myelopathy, meningitis, and various neuropathies.
• Specific conditions mentioned are Guillain-Barré-like syndrome, myasthenic syndrome, and peripheral neuropathies.
• These events stem from the abnormal immune activation induced by ICIs.

Conclusions:

• While ICIs offer significant survival benefits in cancer, they carry a risk of inducing autoimmune disorders.
• Prompt diagnosis and management of neurological adverse events are crucial to minimize patient morbidity.